Medical robotics company Myomo Inc. goes public with IPO offering of $5 million at $7.50 per share. The Cambridge, Mass., company specializes in mobility devices for the arms and hands.

Edwards Lifesciences Corp. won FDA approval for its Sapien 3 transcatheter heart valve device for aortic and mitral valve-in-valve procedures. The Irvine, Calif.-based company leads the way in a burgeoning sector of the market with the expanded indication. The minimally invasive valve procedure device segment for patients who are not indicated for traditional surgery is expected to grow over the next decade, analysts predict. "The global transcatheter heart valve replacement and repair [THVR] market was valued at $1.6 billion in 2015 and is expected to expand at a CAGR of 13.9 percent over the forecast...

Edwards Lifesciences Corp. won FDA approval for its Sapien 3 transcatheter heart valve device for aortic and mitral valve-in-valve procedures. The Irvine, Calif.-based company leads the way in a burgeoning sector of the market with the expanded indication. The minimally invasive valve procedure device segment for patients who are not indicated for traditional surgery is expected to grow over the next decade, analysts predict.

Claret Medical Inc. won FDA clearance for its Sentinel device to capture debris from a transcatheter aortic valve replacement (TAVR) and reduce risk of stroke. Touted by the Santa Rosa, Calif.-based company as the first of its kind in the U.S., the device blocks microphages, fibrin and cholesterol materials loosened during the procedure which can then travel to the brain.